Ascelia Pharma AB (publ) (ACE) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ascelia Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.942 -- 00:00:06.696 Thank you and welcome everyone to the webcast for Acelia Pharma's Q1 report for 2025. 00:00:07.509 -- 00:00:11.110 On this call, we will be making forward-looking statements. 00:00:11.693 -- 00:00:15.617 On today's call, we'll start with the recent key events and then head into our portfolio 00:00:15.617 -- 00:00:19.761 update before moving to financials and priorities ahead. 00:00:19.761 -- 00:00:23.273 After the presentation, we will open up for questions. 00:00:23.273 -- 00:00:27.236 As mentioned, I am Magnus Krofertson, CEO of Acelia Pharma, and with me today I have 00:00:27.236 -- 00:00:33.678 Julie Veras Broeckren, Deputy CEO, and Andreas Norlin, Chief Scientific Officer. 00:00:34.680 -- 00:00:39.723 At Acelia Pharma, we identify, develop, and commercialize novel drugs that address unmet 00:00:39.723 -- 00:00:42.665 medical needs within rare cancer conditions. 00:00:42.665 -- 00:00:48.197 We have two drugs in our pipeline. Orviglands is in registration phase as we have successfully 00:00:48.197 -- 00:00:53.281 completed the pivotal phase three clinical study SPARQL and we are preparing the MDA 00:00:53.281 -- 00:00:55.062 submission. 00:00:55.062 -- 00:00:59.746 Orviglands has orphan drug designation from the FDA and is targeting an addressable market 00:00:59.746 -- 00:01:03.127 opportunity of $800 million globally. 00:01:03.369 -- 00:01:07.712 Oncrawl is ready to start phase two in the treatment of gastric cancer based on encouraging 00:01:07.712 -- 00:01:11.952 results in phase one and a high level of unmet medical need. 00:01:11.952 -- 00:01:16.273 We're based in Malmö, Sweden, and are listed on NASDAQ Stockholm. 00:01:16.934 -- 00:01:21.515 The first quarter of 2025 was eventful as we continued our preparation for the su...